Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: Towards a candidate biomarker

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Vilgrain, Isabelle ^a,b,c   Sidibé, Adama ^a,b,c   Polena, Helena ^a,b,c   Cand, Francine ^a,b,c   Mannic, Tiphaine ^a,b,c,f   Arboleas, Mélanie ^a,b,c   Boccard, Sandra ^a,b,c,g   Baudet, Antoine ^d   Gulino Debrac, Danielle ^a,b,c   Bouillet, Laurence ^a,b,c,d   Quesada, Jean Louis ^d   Mendoza, Christophe ^d   Lebas, Jean François ^d   Pelletier, Laurent ^b,d,e   Berger, François ^b,d,e  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c CEA GRENOBLE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; PROTEIN TYROSINE KINASE; TUMOR MARKER; TYROSINE; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL; BRAIN TUMOR; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; FEMALE; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL CADHERIN BLOOD LEVEL;

ADULT; AGED; ANTIGENS, CD; BRAIN NEOPLASMS; CADHERINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84892905921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080056     Document Type: Article

References (52)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4: 278-299. doi:10.1093/neuonc/4.4.278. PubMed: 12356358.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. doi:10.1007/s00401-007-0243-4. PubMed: 17618441.
4. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307. doi:10.1038/nature10144. PubMed: 21593862.
5. Long DM (1970) Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32: 127-144. doi:10.3171/jns.1970.32. 2.0127. PubMed: 5411991.
6. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT (2008) Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 21: 728-735. doi:10.1097/WCO.0b013e328318402a. PubMed: 18989120.
7. Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D et al. (2010) An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer 9: 234. doi:10.1186/1476-4598-9-234. PubMed: 20822523.
8. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R et al. (1999) Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A 96: 9815-9820. doi:10.1073/pnas.96. 17.9815. PubMed: 10449777.
9. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG et al. (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100: 905-911. doi:10.1182/blood.V100.3.905. PubMed: 12130501.
10. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W (1998) Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111 (13): 1853-1865. PubMed: 9625748.
11. Dejana E, Orsenigo F, Lampugnani MG (2008) The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121: 2115-2122. doi:10.1242/jcs.017897. PubMed: 18565824.
12. Hudry-Clergeon H, Stengel D, Ninio E, Vilgrain I (2005) Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3′-kinase. FASEB J 19: 512-520. doi:10.1096/fj.04-2202com. PubMed: 15791001.
13. Lambeng N, Wallez Y, Rampon C, Cand F, Christé G et al. (2005) Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ Res 96: 384-391. doi:10.1161/01.RES.0000156652. 99586.9f. PubMed: 15662029.
14. fraser HM (2007) Regulation of angiogenesis in the ovary. Angiogenesis in endocrine tissues. Trivandrum. India: Vilgrain I. pp. 73-97
15. Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S et al. (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26: 1067-1077. doi:10.1038/sj.onc.1209855. PubMed: 16909109.
16. Bouillet L, Mannic T, Arboleas M, Subileau M, Massot C et al. (2011) Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol 128: 232-234. doi:10.1016/j.jaci.2011.02.017. PubMed: 21439626.
17. Sidibé A, Mannic T, Arboleas M, Subileau M, Gulino-Debrac D et al. (2012) Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage. Arthritis Rheum 64: 77-87. doi:10.1002/art.33336. PubMed: 21905018.
18. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111. doi:10.1016/j.gde.2004.12.005. PubMed: 15661540.
19. Hermant B, Bibert S, Concord E, Dublet B, Weidenhaupt M et al. (2003) Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem 278: 14002-14012. doi:10.1074/jbc.M300351200. PubMed: 12584200.
20. Identification of membrane calcium channels e... [Growth Factors. 2001] -. NCBI (n.d.). Available: http://www.ncbi.nlm.nih.gov/pubmed/11678208. Accessed 24 June 2013
21. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika: 239-241.
22. Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78: 281-293. doi:10.1007/s11060-005-9097-6. PubMed: 16554966.
23. Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M et al. (1994) Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344: 82-86. doi:10.1016/S0140-6736(94)91280-7. PubMed: 7516992.
24. Hunter T (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21: 140-146. doi:10.1016/j.ceb.2009.01.028. PubMed: 19269802.
25. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110. doi:10.1016/j.ccr.2009.12.020. PubMed: 20129251.
26. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J et al. (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4: 915-924. doi:10.1016/S1097-2765(00)80221-X. PubMed: 10635317.
27. Weis S, Shintani S, Weber A, Kirchmair R, Wood M et al. (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 113: 885-894. doi:10.1172/JCI20702. PubMed: 15067321.
28. Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I (2001) Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J 360: 255-264. doi:10.1042/0264-6021:3600255. PubMed: 11696015.
29. Imamoto A, Soriano P (1993) Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell 73: 1117-1124. doi:10.1016/0092-8674(93) 90641-3. PubMed: 7685657.
30. Pedraza LG, Stewart RA, Li D-M, Xu T (2004) Drosophila Src-family kinases function with Csk to regulate cell proliferation and apoptosis. Oncogene 23: 4754-4762. doi:10.1038/sj.onc.1207635. PubMed: 15107833.
31. Potter MD, Barbero S, Cheresh DA (2005) Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem 280: 31906-31912. doi:10.1074/jbc. M505568200. PubMed: 16027153.
32. Baumeister U, Funke R, Ebnet K, Vorschmitt H, Koch S et al. (2005) Association of Csk to VE-cadherin and inhibition of cell proliferation. EMBO J 24: 1686-1695. doi:10.1038/sj.emboj.7600647. PubMed: 15861137.
33. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848. doi:10.1038/359845a0. PubMed: 1279432.
34. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG et al. (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622. doi:10.1038/nrn2175. PubMed: 17643088.
35. Haas TL, Madri JA (1999) Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9: 70-77. doi:10.1016/S1050-1738(99)00014-6. PubMed: 10578520.
36. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501. doi:10.1038/nrc1121. PubMed: 12835669.
37. Brasch J, Harrison OJ, Ahlsen G, Carnally SM, Henderson RM et al. (2011) Structure and binding mechanism of vascular endothelial cadherin: a divergent classical cadherin. J Mol Biol 408: 57-73. doi:10.1016/j.jmb.2011.01.031. PubMed: 21269602.
38. Hormigo A, Gutin PH, Rafii S (2007) Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 11: 6-8. doi:10.1016/j.ccr.2006.12.008. PubMed: 17222788.
39. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L et al. (2009) Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64: 819-827; discussion: 10.1227/01.NEU.0000343742.06625.DB. PubMed: 19404145.
40. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN et al. (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 756-784. doi:10.1101/gad.187922.112. PubMed: 22508724.
41. Feng H, Hu B, Liu K-W, Li Y, Lu X et al. (2011) Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 121: 4670-4684. doi:10.1172/JCI58559. PubMed: 22080864.
42. Chi AS, Sorensen AG, Jain RK, Batchelor TT (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14: 621-636. doi:10.1634/theoncologist.2008-0272. PubMed: 19487335.
43. Farias-Eisner G, Bank AM, Hwang BY, Appelboom G, Piazza MA et al. (2012) Glioblastoma biomarkers from bench to bedside: advances and challenges. Br J Neurosurg 26: 189-194. doi:10.3109/02688697.2011.629698. PubMed: 22176646.
44. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC et al. (2010) Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 120: 585-592. doi:10.1007/s00401-010-0750-6. PubMed: 20862485.
45. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59: 1169-1180. doi:10.1002/glia.21136. PubMed: 21446047.
46. Nagy JA, Feng D, Vasile E, Wong WH, Shih S-C, et al. (2006) Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab Invest 86: 767-780 doi:10.1038/labinvest.3700436.
47. Conjugated eicosapentaenoic acid inhibits vascular en... [J Nutr. 2007] -. NCBI (n.d.). Available: http://www.ncbi.nlm.nih.gov/pubmed/17311953. Accessed 24 June 2013
48. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA et al. (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging - pilot study. Radiology 255: 622-628. doi:10.1148/radiol.10091341. PubMed: 20413772.
49. Jiang Z, Le Bas J-F, Grand S, Salon C, Pasteris C et al. (2011) Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study. J Neuroradiol 38: 53-61. doi:10.1016/j.neurad.2010.03.004. PubMed: 20554324.
50. Sitohy B, Nagy JA, Jaminet S-CS, Dvorak HF (2011) Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 71: 7021-7028. doi:10.1158/0008-5472.CAN-11-1693. PubMed: 21937680.
51. Petricoin EF, Belluco C, Araujo RP, Liotta LA (2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6: 961-967. doi:10.1038/nrc2011. PubMed: 17093504.
52. Ebos JML, Lee CR, Bogdanovic E, Alami J, Van Slyke P et al. (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529. doi:10.1158/0008-5472.CAN-07-3217. PubMed: 18199548.